These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 17003921)

  • 1. A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate.
    Sørensen B; Ingerslev J
    Thromb Haemost; 2006 Oct; 96(4):446-53. PubMed ID: 17003921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E; Heitmeier S; Laux V; Buchmüller A
    Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate.
    Lindahl TL; Wallstedt M; Gustafsson KM; Persson E; Hillarp A
    Thromb Res; 2015 Mar; 135(3):544-7. PubMed ID: 25596769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
    Elg M; Carlsson S; Gustafsson D
    Thromb Res; 2001 Feb; 101(3):159-70. PubMed ID: 11228339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole blood coagulation in children with thrombocytopenia and the response to platelet replacement, recombinant factor VIIa, and a potent factor VIIa analogue.
    Larsen OH; Clausen N; Persson E; Ezban M; Ingerslev J; Sørensen B
    Br J Haematol; 2009 Jan; 144(1):99-106. PubMed ID: 19016728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.
    Sørensen B; Persson E; Ingerslev J
    Br J Haematol; 2007 Apr; 137(2):158-65. PubMed ID: 17391496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa.
    Sørensen B; Ingerslev J
    J Thromb Haemost; 2004 Jan; 2(1):102-10. PubMed ID: 14717973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
    Wolzt M; Levi M; Sarich TC; Boström SL; Eriksson UG; Eriksson-Lepkowska M; Svensson M; Weitz JI; Elg M; Wåhlander K
    Thromb Haemost; 2004 Jun; 91(6):1090-6. PubMed ID: 15175794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
    Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
    Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates.
    Gruber A; Carlsson S; Kotzé HF; Marzec U; Sarich TC; Hanson SR
    Thromb Res; 2007; 119(1):121-7. PubMed ID: 16448687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of the International Normalized Ratio with recombinant activated factor VII in central nervous system bleeding during warfarin thromboprophylaxis: clinical and biochemical aspects.
    Sørensen B; Johansen P; Nielsen GL; Sørensen JC; Ingerslev J
    Blood Coagul Fibrinolysis; 2003 Jul; 14(5):469-77. PubMed ID: 12851533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
    Martin AC; Gouin-Thibault I; Siguret V; Mordohay A; Samama CM; Gaussem P; Le Bonniec B; Godier A
    J Thromb Haemost; 2015 Mar; 13(3):426-36. PubMed ID: 25630710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant factor VIIa and fibrinogen display additive effect during in vitro haemodilution with crystalloids.
    Fenger-Eriksen C; Tønnesen E; Ingerslev J; Sørensen B
    Acta Anaesthesiol Scand; 2009 Mar; 53(3):332-8. PubMed ID: 19243319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Citrate artificially masks the haemostatic effect of recombinant factor VIIa in dilutional coagulopathy.
    Fenger-Eriksen C; Ingerslev J; Tønnesen E; Sørensen B
    Ann Hematol; 2009 Mar; 88(3):255-60. PubMed ID: 18696068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
    Carr ME; Martin EJ; Kuhn JG; Seremetis SV
    Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
    Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
    Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro effect of activated recombinant factor VII (rFVIIa) on coagulation properties of human blood at hypothermic temperatures.
    Kheirabadi BS; Delgado AV; Dubick MA; Scherer MR; Fedyk CG; Holcomb JB; Pusateri AE
    J Trauma; 2007 Nov; 63(5):1079-86. PubMed ID: 17993954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
    Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
    Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood.
    Gerotziafas GT; Depasse F; Chakroun T; Samama MM; Elalamy I
    Thromb Haemost; 2004 Mar; 91(3):531-7. PubMed ID: 14983229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.